Ayalew Tefferi MD on Imetelstat as Therapy for Myelofibrosis

Linda J. Burns, MD, on the BLAST Study

2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 379, “BLAST: A Confirmatory, Single-Arm, Phase II Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE) Antibody Construct, in Patients with Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia (ALL),” presented by Nicola Gökbuget, MD.

Time: 1:11

Myelodysplastic Syndromes

Alan F. List, MD

Alan F. List, MD, on Rigosertib in Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome

Alan F. List, MD, of Moffitt Cancer Center, offers his thoughts on abstract 163, “Overall Survival and Subgroup Analysis From a Randomized Phase III Study of Intravenous Rigosertib vs Best Supportive Care in Patients With Higher-Risk Myelodysplastic Syndrome After Failure of Hypomethylating Agents,” presented by Guillermo Garcia-Manero, MD.

Time: 1:54

Lymphoma

Laurie Sehn, MD

Laurie Sehn, MD, on Brentuximab Vedotin in Diffuse Large B-Cell Lymphoma With Undetectable CD30

Laurie Sehn, MD, of the BC Cancer Agency, on abstract 629, “Brentuximab Vedotin Monotherapy in Diffuse Large B-Cell Lymphoma Patients With Undetectable CD30: Preliminary Results From a Phase II Study.”

Leukemia

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Progress Made Against AML and APL

James. O Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Richard M. Stone, MD, of the Dana-Farber Cancer Institute, discuss advances in treating acute myeloid leukemia and the acute promyelocytic leukema subtype.

Lymphoma

Bertrand Coiffier, MD

Bertrand Coiffier, MD, PhD, on the RO-CHOP Study

Bertrand Coiffier, MD, PhD, of Centre Hospitalier Lyon-Sud, offers his thoughts on abstract 504, “Final Analysis of the RO-CHOP Phase Ib/II Study: Romidepsin in Association With CHOP in Patients With Peripheral T-Cell Lymphoma (PTCL)” presented by Jehan Dupuis, MD.

Time: 1:53

Ayalew Tefferi, MD, on Imetelstat as Therapy for Myelofibrosis

Related Videos

Linda J. Burns, MD, on the BLAST Study

Alan F. List, MD, on Rigosertib in Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome

Laurie Sehn, MD, on Brentuximab Vedotin in Diffuse Large B-Cell Lymphoma With Undetectable CD30

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Progress Made Against AML and APL

Bertrand Coiffier, MD, PhD, on the RO-CHOP Study

ACS Study Quantifies Financial Burden of Cancer in Older Patients

Transplant Consolidation Improves Survival in Primary CNS Lymphoma

Pirtobrutinib Triplet Improves Progression-Free Survival in Previously Treated CLL

NCI Names New CCR Director

Rectal Cancer AI Identifies Patients Most Likely to Benefit From Irinotecan-Intensified Neoadjuvant Chemoradiotherapy